Search Result
Results for "
DMPE-PEG2000
" in MedChemExpress (MCE) Product Catalog:
-
- HY-144006
-
|
14:0 PEG2000 PE ammonium; 1,2-Dimyristoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] ammonium
|
Liposome
|
Others
|
|
DMPE-PEG2000 ammonium (14:0 PEG2000 PE ammonium) is a PEG-phospholipid conjugate to prepare nanostructured lipid carrier .
|
-
-
- HY-P10392AF
-
|
|
Wnt
β-catenin
|
Cancer
|
|
fStAx-35R TFA is the hydrocarbon-stapled peptide. fStAx-35R TFA inhibits Wnt/β-catenin signaling pathway by disrupting the β-catenin-TCF interaction. fStAx-35R TFA can be used in cancer research .
|
-
-
- HY-P10896
-
|
|
Bombesin Receptor
|
Cancer
|
|
NOTA-P2-RM26 is an antagonist of Bombesin (HY-P0195) analogs, and the gastrin-releasing peptide receptor (GRPR/BB2) is a molecular target for prostate cancer visualization. NOTA-P2-RM26 is labeled with 111In and 68Ga for prostate cancer imaging studies using PET and SPECT/CT .
|
-
-
- HY-166857
-
|
|
Biochemical Assay Reagents
|
Others
|
|
DMPE-PEG2000-amineTFA is a phospholipid. Phospholipids have good biocompatibility and significant amphiphilic characteristics, making them the main and suitable dosage form or excipient in drug formulations, thereby achieving better therapeutic effects. DMPE-PEG2000-amineTFAcan be used in drug delivery research .
|
-
-
- HY-182841A
-
|
DMPE-PEG2000-Thiol
|
Biochemical Assay Reagents
|
Others
|
|
DMPE-PEG2000-SH (DMPE-PEG2000-Thiol) is a conjugate composed of DMPE, a PEG chain, and a terminal thiol group (-SH). The thiol group in DMPE-PEG2000-SH exhibits strong chemical reactivity and can participate in various bioconjugation reactions for targeted modification of liposomes/nanoparticles.
|
-
-
- HY-182836A
-
|
DMPE-PEG2000-Azide
|
Biochemical Assay Reagents
|
Others
|
|
DMPE-PEG2000-N3 (DMPE-PEG2000-Azide) is a conjugate composed of DMPE, PEG chains, and terminal azido groups (-N3). DMPE-PEG2000-Azide is a click chemistry reagent used for the targeted modification of liposomes/nanoparticles.
|
-
-
- HY-W1052298
-
|
DMPE-PEG2000-Amine
|
Biochemical Assay Reagents
|
Others
|
|
DMPE-PEG2000-NH2 (DMPE-PEG2000-Amine) is a conjugate composed of DMPE, a PEG chain, and a terminal primary amino group (-NH2). The primary amino group in DMPE-PEG2000-NH2 can be covalently linked to functional groups such as carboxylic acids, NHS esters, and isocyanates for targeted modification of liposomes/nanoparticles.
|
-
-
- HY-169232
-
|
|
PROTACs
|
Cancer
|
|
PCC16 chloride is a CRBN-based cp-PCC with an IC50 value of 102 nM for the degradation of DHHC3. PCC16 chloride has antitumor activity. (Target protein ligand: HY-169235, linker: HY-169236, E3 ligase ligand: HY-10984) .
|
-
-
- HY-W1052117
-
|
|
Biochemical Assay Reagents
|
Others
|
|
DMPE-PEG2000-COOH is a conjugate composed of DMPE, a PEG chain, and a terminal carboxyl group (-COOH). The carboxyl group in DMPE-PEG2000-COOH can form an amide bond with a primary amine via EDC/NHS activation, enabling targeted modification of liposomes/nanoparticles.
|
-
-
- HY-W1052227
-
|
|
Biochemical Assay Reagents
|
Others
|
|
DMPE-PEG2000-Mal is a conjugate composed of DMPE, PEG chains, and maleimide (Mal). The maleimide group in DMPE-PEG2000-Mal can undergo a specific Michael addition reaction with thiol-containing (-SH) biomolecules (such as peptides, antibodies, and aptamers), enabling targeted modification of liposomes/nanoparticles.
|
-
-
- HY-183016A
-
|
|
Biochemical Assay Reagents
|
Others
|
|
DMPE-PEG2000-NHS is a conjugate composed of DMPE, PEG chains, and terminal active esters (NHS). The NHS ester in DMPE-PEG2000-NHS can rapidly covalently react with molecules containing primary amines (such as proteins, peptides, and small molecules modified with amino groups) to form stable amide bonds, enabling targeted modification of liposomes/nanoparticles.
|
-
-
- HY-W1052298D
-
|
DMPE-PEG10000-Amine
|
Biochemical Assay Reagents
|
|
|
DMPE-PEG2000-NH2 (DMPE-PEG2000-Amine) is a conjugate composed of DMPE, a PEG chain, and a terminal primary amino group (-NH2). The primary amino group in DMPE-PEG2000-NH2 can be covalently linked to functional groups such as carboxylic acids, NHS esters, and isocyanates for targeted modification of liposomes/nanoparticles.
|
-
-
- HY-182833A
-
|
|
Biochemical Assay Reagents
|
Others
|
|
DPPE-PEG2000-NHS is a conjugate composed of DPPE, PEG chains, and terminal active esters (NHS). The NHS ester in DMPE-PEG2000-NHS can rapidly covalently react with molecules containing primary amines (such as proteins, peptides, and small molecules modified with amino groups) to form stable amide bonds, enabling targeted modification of liposomes/nanoparticles.
|
-
-
- HY-P11625
-
|
|
RXFP Receptor
|
Cardiovascular Disease
|
|
R9-13 is a fatty acid-conjugated relaxin and an agonist of LGR7 (RXFP1). R9-13 induces sustained pubic symphysis elongation in estrogen-pretreated mice. R9-13 exhibits long-acting pharmacokinetic profiles in rodents, with in vivo activity lasting up to one week after administration. R9-13 can be used in studies related to acute heart failure .
|
-
-
- HY-P11830
-
|
|
Amylin Receptor
|
Metabolic Disease
|
|
UDA-6 is a potent calcitonin and amylin receptor agonist (DACRA). UDA-6 induces weight loss, improves metabolic and hepatic parameters, and stabilizes active receptor states in obesity rats. UDA-6 can be used for the research of obesity .
|
-
-
- HY-P11596
-
|
|
Integrin
|
Cancer
|
|
NOTA-Asp2-αvβ6L is an integrin αvβ6 binder with selective accumulation in αvβ6-positive pancreatic cancer cells and tumors. NOTA-Asp2-αvβ6L can be used as a PET/CT tracer for imaging pancreatic ductal adenocarcinoma (PDAC) .
|
-
-
- HY-P3252AS
-
|
|
Isotope-Labeled Compounds
Complement System
|
Inflammation/Immunology
|
|
Pegcetacoplan- 13C3, 15N TFA is the 13C- and 15N-labeled Pegcetacoplan TFA. Pegcetacoplan is a pegylated complement C3/C3b inhibitor. Pegcetacoplan acts by specifically binding to and inhibiting C3 and C3b, thereby suppressing the complement cascade at its proximal stage. Pegcetacoplan is not a known inhibitor or inducer of CYP450 isoenzymes. Pegcetacoplan can be used for the research of complement-mediated diseases, including paroxysmal nocturnal hemoglobinuria (PNH) and age-related macular degeneration (AMD).
|
-
-
- HY-144006
-
|
14:0 PEG2000 PE ammonium; 1,2-Dimyristoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] ammonium
|
生化学アッセイ試薬
|
|
DMPE-PEG2000 ammonium (14:0 PEG2000 PE ammonium) is a PEG-phospholipid conjugate to prepare nanostructured lipid carrier .
|
-
- HY-166857
-
|
|
生化学アッセイ試薬
|
|
DMPE-PEG2000-amineTFA is a phospholipid. Phospholipids have good biocompatibility and significant amphiphilic characteristics, making them the main and suitable dosage form or excipient in drug formulations, thereby achieving better therapeutic effects. DMPE-PEG2000-amineTFAcan be used in drug delivery research .
|
-
- HY-182841A
-
|
DMPE-PEG2000-Thiol
|
生化学アッセイ試薬
|
|
DMPE-PEG2000-SH (DMPE-PEG2000-Thiol) is a conjugate composed of DMPE, a PEG chain, and a terminal thiol group (-SH). The thiol group in DMPE-PEG2000-SH exhibits strong chemical reactivity and can participate in various bioconjugation reactions for targeted modification of liposomes/nanoparticles.
|
-
- HY-182836A
-
|
DMPE-PEG2000-Azide
|
生化学アッセイ試薬
|
|
DMPE-PEG2000-N3 (DMPE-PEG2000-Azide) is a conjugate composed of DMPE, PEG chains, and terminal azido groups (-N3). DMPE-PEG2000-Azide is a click chemistry reagent used for the targeted modification of liposomes/nanoparticles.
|
-
- HY-W1052298
-
|
DMPE-PEG2000-Amine
|
生化学アッセイ試薬
|
|
DMPE-PEG2000-NH2 (DMPE-PEG2000-Amine) is a conjugate composed of DMPE, a PEG chain, and a terminal primary amino group (-NH2). The primary amino group in DMPE-PEG2000-NH2 can be covalently linked to functional groups such as carboxylic acids, NHS esters, and isocyanates for targeted modification of liposomes/nanoparticles.
|
-
- HY-W1052117
-
|
|
生化学アッセイ試薬
|
|
DMPE-PEG2000-COOH is a conjugate composed of DMPE, a PEG chain, and a terminal carboxyl group (-COOH). The carboxyl group in DMPE-PEG2000-COOH can form an amide bond with a primary amine via EDC/NHS activation, enabling targeted modification of liposomes/nanoparticles.
|
-
- HY-W1052227
-
|
|
生化学アッセイ試薬
|
|
DMPE-PEG2000-Mal is a conjugate composed of DMPE, PEG chains, and maleimide (Mal). The maleimide group in DMPE-PEG2000-Mal can undergo a specific Michael addition reaction with thiol-containing (-SH) biomolecules (such as peptides, antibodies, and aptamers), enabling targeted modification of liposomes/nanoparticles.
|
-
- HY-183016A
-
|
|
生化学アッセイ試薬
|
|
DMPE-PEG2000-NHS is a conjugate composed of DMPE, PEG chains, and terminal active esters (NHS). The NHS ester in DMPE-PEG2000-NHS can rapidly covalently react with molecules containing primary amines (such as proteins, peptides, and small molecules modified with amino groups) to form stable amide bonds, enabling targeted modification of liposomes/nanoparticles.
|
-
- HY-W1052298D
-
|
DMPE-PEG10000-Amine
|
生化学アッセイ試薬
|
|
DMPE-PEG2000-NH2 (DMPE-PEG2000-Amine) is a conjugate composed of DMPE, a PEG chain, and a terminal primary amino group (-NH2). The primary amino group in DMPE-PEG2000-NH2 can be covalently linked to functional groups such as carboxylic acids, NHS esters, and isocyanates for targeted modification of liposomes/nanoparticles.
|
-
- HY-182833A
-
|
|
生化学アッセイ試薬
|
|
DPPE-PEG2000-NHS is a conjugate composed of DPPE, PEG chains, and terminal active esters (NHS). The NHS ester in DMPE-PEG2000-NHS can rapidly covalently react with molecules containing primary amines (such as proteins, peptides, and small molecules modified with amino groups) to form stable amide bonds, enabling targeted modification of liposomes/nanoparticles.
|
-
- HY-P10392AF
-
|
|
Wnt
β-catenin
|
Cancer
|
|
fStAx-35R TFA is the hydrocarbon-stapled peptide. fStAx-35R TFA inhibits Wnt/β-catenin signaling pathway by disrupting the β-catenin-TCF interaction. fStAx-35R TFA can be used in cancer research .
|
-
- HY-P10896
-
|
|
Bombesin Receptor
|
Cancer
|
|
NOTA-P2-RM26 is an antagonist of Bombesin (HY-P0195) analogs, and the gastrin-releasing peptide receptor (GRPR/BB2) is a molecular target for prostate cancer visualization. NOTA-P2-RM26 is labeled with 111In and 68Ga for prostate cancer imaging studies using PET and SPECT/CT .
|
-
- HY-169232
-
|
|
PROTACs
|
Cancer
|
|
PCC16 chloride is a CRBN-based cp-PCC with an IC50 value of 102 nM for the degradation of DHHC3. PCC16 chloride has antitumor activity. (Target protein ligand: HY-169235, linker: HY-169236, E3 ligase ligand: HY-10984) .
|
-
- HY-P11625
-
|
|
RXFP Receptor
|
Cardiovascular Disease
|
|
R9-13 is a fatty acid-conjugated relaxin and an agonist of LGR7 (RXFP1). R9-13 induces sustained pubic symphysis elongation in estrogen-pretreated mice. R9-13 exhibits long-acting pharmacokinetic profiles in rodents, with in vivo activity lasting up to one week after administration. R9-13 can be used in studies related to acute heart failure .
|
-
- HY-P11830
-
|
|
Amylin Receptor
|
Metabolic Disease
|
|
UDA-6 is a potent calcitonin and amylin receptor agonist (DACRA). UDA-6 induces weight loss, improves metabolic and hepatic parameters, and stabilizes active receptor states in obesity rats. UDA-6 can be used for the research of obesity .
|
-
- HY-P11596
-
|
|
Integrin
|
Cancer
|
|
NOTA-Asp2-αvβ6L is an integrin αvβ6 binder with selective accumulation in αvβ6-positive pancreatic cancer cells and tumors. NOTA-Asp2-αvβ6L can be used as a PET/CT tracer for imaging pancreatic ductal adenocarcinoma (PDAC) .
|
-
- HY-P3252AS
-
|
|
Isotope-Labeled Compounds
Complement System
|
Inflammation/Immunology
|
|
Pegcetacoplan- 13C3, 15N TFA is the 13C- and 15N-labeled Pegcetacoplan TFA. Pegcetacoplan is a pegylated complement C3/C3b inhibitor. Pegcetacoplan acts by specifically binding to and inhibiting C3 and C3b, thereby suppressing the complement cascade at its proximal stage. Pegcetacoplan is not a known inhibitor or inducer of CYP450 isoenzymes. Pegcetacoplan can be used for the research of complement-mediated diseases, including paroxysmal nocturnal hemoglobinuria (PNH) and age-related macular degeneration (AMD).
|
-
- HY-P3252AS
-
|
|
|
Pegcetacoplan- 13C3, 15N TFA is the 13C- and 15N-labeled Pegcetacoplan TFA. Pegcetacoplan is a pegylated complement C3/C3b inhibitor. Pegcetacoplan acts by specifically binding to and inhibiting C3 and C3b, thereby suppressing the complement cascade at its proximal stage. Pegcetacoplan is not a known inhibitor or inducer of CYP450 isoenzymes. Pegcetacoplan can be used for the research of complement-mediated diseases, including paroxysmal nocturnal hemoglobinuria (PNH) and age-related macular degeneration (AMD).
|
-
-
- HY-182836A
-
|
DMPE-PEG2000-Azide
|
|
Azide
|
|
DMPE-PEG2000-N3 (DMPE-PEG2000-Azide) is a conjugate composed of DMPE, PEG chains, and terminal azido groups (-N3). DMPE-PEG2000-Azide is a click chemistry reagent used for the targeted modification of liposomes/nanoparticles.
|
-
- HY-144006
-
|
14:0 PEG2000 PE ammonium; 1,2-Dimyristoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] ammonium
|
|
Pegylated Lipids
|
|
DMPE-PEG2000 ammonium (14:0 PEG2000 PE ammonium) is a PEG-phospholipid conjugate to prepare nanostructured lipid carrier .
|
-
- HY-166857
-
|
|
|
Pegylated Lipids
|
|
DMPE-PEG2000-amineTFA is a phospholipid. Phospholipids have good biocompatibility and significant amphiphilic characteristics, making them the main and suitable dosage form or excipient in drug formulations, thereby achieving better therapeutic effects. DMPE-PEG2000-amineTFAcan be used in drug delivery research .
|
入力情報は安全に管理されます. ※ 必須入力項目.
Inquiry Information
- 製品名:
- 製品番号:
- 数量:
- MCE 日本正規代理店:
